Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Afimetoran
BMS-986256 · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| Afimetoran: Dose 1 | EXPERIMENTAL | - |
| Afimetoran: Dose 2 | EXPERIMENTAL | - |
| Afimetoran: Dose 3 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| BMS-986256 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Afimetoran | DRUG | Specified dose on specified days |
| Placebo | OTHER | Specified dose on specified days |
| BMS-986256 | DRUG | Specified Dose on Specified Days |
| BMS-986256 Placebo | OTHER | Specified Dose on Specified Days |
Inclusion Criteria: * Diagnosed ≥ 12 weeks before the screening visit and qualify as having SLE according to the SLE International Collaborating Clinics (SLICC) Classification Criteria at the screening visit * Test positive, as determined by the central laboratory, for at least one of the following...
BMS-986256 is an investigational small molecule being developed by Bristol-Myers Squibb for cutaneous lupus erythematosus, a form of lupus that affects the skin. It has been studied in a Phase 1 clinical trial and is not approved for any use.
BMS-986256 is being studied for the treatment of active cutaneous lupus erythematosus, a skin manifestation of lupus. Its only clinical trial enrolled participants with this condition. It is investigational and has not been approved for treating cutaneous lupus or any other indication.
BMS-986256 is developed by Bristol-Myers Squibb Company, which trades on the New York Stock Exchange under the ticker BMY. The company sponsored the Phase 1 study of the compound in participants with active cutaneous lupus erythematosus.
BMS-986256 is in Phase 1 development. One Phase 1 trial has been completed, and no trials are currently active. The drug remains investigational and has not been approved by the FDA or any other regulatory agency for cutaneous lupus erythematosus.
BMS-986256 has been evaluated in one clinical trial, NCT04493541, titled A Study to Assess the Safety and Drug Levels of BMS-986256 in Participants With Active Cutaneous Lupus Erythematosus. The Phase 1 trial was completed, enrolled 13 participants in Germany, and was randomized, double-blind, and placebo-controlled.
The Phase 1 trial NCT04493541 assessed the safety and drug levels of BMS-986256 in adults with active cutaneous lupus erythematosus. It was a randomized, double-blind, placebo-controlled study that enrolled 13 participants aged 18 years and older in Germany. The trial has been completed.